A recent study suggests that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle plans.
Published data in a leading medical journal points out that while obese individuals can lose about a fifth of their body weight while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing such treatments need to be cognizant of the danger of fast weight regain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to starting weight in about a year and a half.
Comparing Approaches
The study, which reviewed 37 of studies involving over 9,000 of participants, compared the effects of GLP-1 agonists with conventional dieting.
Researchers note that individuals who lose weight through diet and exercise typically have a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.
Understanding the Fast Regain
Doctors believe the mechanism of the drugs is key to understanding the accelerated weight return.
The injections imitate a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal might result in the body to generate a reduced amount of its own natural GLP-1, and may also diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' results in hunger is no longer kept in check, making binge eating far more likely."
A Chronic Disease?
Medical guidelines suggest the injections for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians say that, due to the significant potential of relapse, the therapy is often ongoing.
This perspective is supported by pharmaceutical companies, who state that the findings "highlight the chronic character of excess weight," comparing it to managing conditions like hypertension.
Patient Testimonies
Individuals who have stopped the medication describe a intense return of cravings.
"It felt as if something that goes on and I was suddenly ravenous," described one woman.
The struggle is exacerbated if patients have not developed lasting dietary or behavioural modifications during therapy.
Widespread Interest
Survey data show that a significant number of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Adoption is higher among women compared to men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private prescriptions rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent solution and long-term success likely depends on combined behavioural management.
